Pres. Trump Meets With Pharmaceutical Executives on Coronavirus CSPAN March 2, 2020 4:20pm-5:01pm EST
california, colorado, maine, massachusetts, minnesota, north carolina, oklahoma, tennessee, texas, utah, vermont and virginia. with candidate speeches and results coverage begins use it live at 7:00 p.m. eastern on c-span, at c-span.org, or listen from wherever you are with the free c-span radio app. >> the remarks by president trump just beginning as he meets with pharmaceutical executives on the coronavirus outbreak. president trump: dr. brooks has been to the white house a lot over her career. she's now going to be here working with mike pence and everybody full-time and we appreciate it. we appreciate it very much, dr. brooks. a real expert in her field and if you'd like, you could ask her a couple of questions when we're finished. we worked to -- we're working very hard to expedite the longer
process of developing a vaccine. we're also moving with maximum speed to develop therapies so that we can help people recover as quickly as possible. we have a lot of recovery going on. we want to see if we can advance that. it's likely that therapies will be available before a vaccine is actually ready and we'll seek to bring all effective treatments to market as soon as possible. some very good work has been done on the vaccine and they have some good progress and you'll be able to ask a couple of questions of the folks here. we're also working with congress to ensure that america has what it needs to respond to this challenge. great challenge. but everybody's responding very well. since the start of the outbreak, my administration has taken the most aggressive action in history to protect our citizens, including closing our borders very early, a lot earlier than people wanted us to do. and that turned out to be a good decision. i ordered sweeping travel restrictions, increased travel
advisory levels, established screening measures and imposed historic quarantines. we have quarantines all over the country. a lot of the coronavirus shows the importance of bringing manufacturing back to america so that we are producing at home the medicines and equipment and everything else that we need to protect the public's health. i've been talking about this for a long time. that process has already started. it started long before we ever knew about this. we want to make certain things at home. we want to be doing our manufacturing at home. it's not only done in china, it's done in many other places, including ireland and a lot of places make our different drugs and things that we need so badly. it's not good to be dealing with one or two or three countries and we do very little at home and we're going to start doing it at home. we've been talking about that for a long time.
a lot of drug companies are heading back here anyway. the coronavirus shows the importance of bringing all of that manufacturing back to america and we will have that started. it's already started, frankly. it started about a year ago. the white house coronavirus task force, led by vice president mike pence, has been meeting daily and coordinating closely with the state and local governments. mike had a call today with 53 governors and i heard it was a very good call. everybody's very well coordinated and the governors and the states, all of them, they've been really working closely with you us -- with us. it's been a very good relationship. we will confront this challenge together and we will continue to do exactly what we're doing. and we're going to be very successful. a lot of things are happening, a lot of very exciting things are happening and they're happening very rapidly. so with that, i'd like to
introduce mike and you can say a little bit as to your calls and some of the things that are happening today. >> thank you, mr. president. the white house coronavirus task force will be meeting again this afternoon. but as you mentioned earlier today, at your direction we hosted a video and telephone conference wall with 53 governors. vice president pence: we're all in this together. today's meeting is a reflection of the fact that this president understands that industry is a part of the one team in america that's going to address the coronavirus in this country. and i'm grateful for these leaders of the nation's top pharmaceutical companies to come in, to speak to us about the development of vaccines, but also the development of therapeutic medications that can be available in the short term. we're grateful for your participation. the president will also be traveling tomorrow to the national institutes of health, c.d.c., before the week is out.
and we will be meeting with leaders of the airline industry, we'll be meeting with leaders of the cruise line industry. and we welcome the partnership with industry in this country as we work out the president's top priority which is the health and safety and well-being of the american people. let me also extend my welcome to the doctor, one of the leading experts in infectious diseases in the world. she has served in uniform in the united states, she's served in multiple administrations and she's going to be our right arm here as we implement your vision for putting the health and safety and well-being of the american people first. so with that, mr. president, i know secretary azar has a few thoughts and i look forward to the meeting. president trump: alex, maybe you can give a little update and we'll garned the room and people
can introduce themselves, if that's ok. secretary azar: thank you. so we continue to see cases here in the united states. as you know, we tragedy he canly have experienced several more deaths reported today. and our condolences go out to their families, of course. that's why the president's leading this whole of government response at the direction of the vice president. we're here working with the pharmaceutical company leaders on three key issues. how do we speed vaccines and therapeutics and what are the supply chain challenges that we may be facing for pharmaceutical products here in the united states. with regard to therapeutics and vaccines, we want to know how we can not get in their way but rather speed that development process along. want to make sure that they all know that we've got commissioner hahn here from the f.d.a. and this is all in the context of emergency powers, emergency use authorizations and the president will be asking you, how can we make it faster and make anything faster, how can we challenge
some of those normal pharma time lines that can be a little slow and bureaucratic, what can we do to speed that along given the nature of this emergency and be a good partner with you in making that happen? especially once we get the emergency supplemental passed by congress in the next week or so. so, with that said, mr. president, thank you very much. president trump: supplemental is moving along very rapidly. everyone wants to get that done. oving along quickly. >> first of all, i'd like to really say how much we welcome the leadership, mr. president, of this task force. n.i.h. -- [indiscernible] -- and recognize the very successful efforts made by the administration to protect people here in the u.s. as a -- [indiscernible] -- led company with a large manufacturing presence here, we know we have a responsibility and a vital role to play and -- [indiscernible] -- to make sure we make available as part of this one team a pandemic
technology available to any company with a highly promising vaccine. because this new technology could make these other vaccines either bring more efficacy or indeed allow them -- [indiscernible] -- which means it could protect more people which is obviously incredibly important as we're trying to work a pace and scale. we're announced two collaborations and hope to announce more. we're also ready to produce should the u.s. government this.e it, a stockpile of we know fighting covid-19 requires a global effort and the u.s. is a vital leader in this and we're absolutely committed to play our part. president trump: thank you very much. thank you very much. please. go ahead. i'd like you to say something anyway. [laughter] >> i'm the director of the national -- [indiscernible] --
and infectious diseases. very pleased to be on this as if force which i think you're going to see is working extraordinarily smoothly under the leadership of the vice president and secretary azar. as you know, we're involved and that's the reason why i'm pleased to be in this room with you all, because we're involved in the fundamental basic and clinical research to develop calibrations in the form of therapeutics and vaccines and i'm sure i'll be working with many of you around the room and i look forward to. it president trump: thank you very much. >> thank you, mr. president. director of c.d.c. i also want to thank you all for being here. c.d.c.to extend anything can also do as we try to evaluate some of the fruits of your labor. you're here to make that which we have available to help. we're all counting on a new countermeasures to be in the arena pretty quickly. president trump: thank you. >> thank you, mr. president. vice president, thank you for
having me here. i'm the c.e.o. of a clinical stage biotech company. we use technology, optimize molecules, once injected into the body -- [indiscernible] -- on how to make proteins. we can use technology to trigger an immune response against viruses or get the body to increase production of t cells for cancer vaccines. [indiscernible] -- the technology also works well to replace missing proteins so we can work in the rare diseases. one strength of our technology is we can produce vaccines using a very low-dose. for instance, the phase one rabies trial we completed was done at a one microgram dose, a very, very tiny dose. more broadly, our company focuses -- this year we have four programs in phase one clinical trials and the coronavirus program would be the fifth program in phase one. except that the phase one
program for coronavirus will start at the end of june. the technology platform is fast and it's and aisle. we were the first company to have manufacturing. we started in 2016 -- 2006. currently we have three large scale facilities and we are up and running now. today we have a fourth and we're looking for additional --ed [indiscernible] -- put the machinery in there. once we put the machinery in the building, we can make hundreds of millions of doses of the virus virus vaccine. we want to help there. additionally we have developed a fully automated production machine. this automated machine is part of a collaboration and additionally we're working on the coronavirus, they have funded our efforts to get the program and the vaccine through phase one. the key point here being that we believe we can develop the vaccine for covid-19 very quickly and we have the wherewithal to manufacture it although we'd like additional help on our facilities. again, we appreciate the opportunity to be here today and
thank you very much. president trump: thank you very much. appreciate it. john go ahead. >> sure. i'm a head vaccine research -- [indiscernible] -- making vaccines for over 100 years. for this project we're working with proprietary protein technology to make the first flu vaccine -- [indiscernible] -- based on this technology. it has the potential to be applied very readily to the coronavirus. early work done with tsars was very promising. we intend to leverage that work so we can get to the clinic as soon as possible. because we are a major flu vaccine producer, with this technology we have the ability to produce a large amount of vaccine, we predict, dependent on the final formulation, 100 million to 600 million doses per year made in new york and pennsylvania. which is where we've made about 90% of our flu products.
we can do this without jeopardizing our flu vaccine production importantly. because we know that's very important to maintain that. so, mr. president, we're willing to do whatever it takes to work with you and this administration to collaborate with n.i.h. and pharma who has co-sponsored our research to make sure we can do what we can to help with this problem. president trump: when do you think you'd be title of the bill start producing the vaccine? >> we're producing it now. the experimental lot. proteins take somewhat longer than some of the other technologies. but it's a technology that works. we think it will be ready for the clinic in a year. depending upon the nature of how the epidemic goes or doesn't go, with the help of the agencies of this country, perhaps it's several years. difficult to predict. knowing that a vaccine has to be both safe and efficacious because it's given to healthy people. president trump: thank you very much. >> thanks, mr. president, for
having us. i'm the founder and c.e.o. of the generon company that i built over the last 30 years. we are an antibody primarily centered company. we are no strangers to collaborating with the administration. we worked with secretary azar's group and we came up with a cure for ebola. and we're very proud of that. the group was really instrumental in testing that under unbelievable conditions in the congo. it didn't create quite as much excitement because, thank goodness, it didn't hit our shores. but we can use the exact same technology and we already have. we have 1,000 antibodies that are already sitting in dishes. we're screening and selecting them and anticipate if all goes well 200,000 doses per month can come out of our factory in new york starting in august. the unique thing about our technology -- president trump: we'd be title
of the bill use the vaccine that early? >> depends on what we see and how closely we work with the f.d.a., which we will do. the f.d.a. has already reached out to us. we have to work closely -- president trump: that process would be faster than john's? >> it would be. >> can you explain why that would be? >> so we make passive vack -- vaccine and therapeutic -- our drug will be able to protect you , whether or not you're infected, it will protect you from getting infected or if you are infected, it would treat you. we have just taken processes that normally take years, literally years, and we've put them end to end and now do them in weeks to months. nobody else in the industry can do. so we're very excited to collaborate once again. president trump: this would be a combination of a vaccine and also it will make you better quicker. >> if you get immunized, you're
going to make antibodies to protect you. we're going to make those ant beauy -- antibodies and give them to you so you don't have to go through that whole process. ebola, it was life-saving. truly life-saving. beat out the anti-virals. it was the way to go. it's very predictable. i just want to say, i hope everybody succeeds here. bringing everybody together here is really critical and there's going to be success. this industry is really talented as an industry. sometimes we run astray. but we're going to get this done. president trump: thank you very much. appreciate it. >> thank you, mr. president. for the invitation. i'm the c.e.o. of -- proud tonible] -- very be working with the u.s. government and to have only 42 days from the sequence of the virus or vaccine to dr. foxx's team at n.i.h. waiting for a vaccine to be green-lighted from the f.d.a. so
the team can stop that as soon as possible. what's very interesting about the technology is we use -- [indiscernible] -- so basically -- [indiscernible] -- quickly from virgin information of the virus to having it's a convenient -- vaccine. we have a vaccine in the clinic. we have five of those -- department of] -- defense, h.h.s., we're having ongoing discussions. we're working with the n.i.h. and we've worked with a team on the mers vaccine for the middle east, which is the crones virus -- coronavirus. we're able to make very fast from a few phones, to getting a vaccine made already. we're working on the phase two material. as soon as we get the phase one out of the n.i.h., we'll able to start phase two right away. president trump: what is your
timing? >> we're hoping to get the phase one very soon now. we're just waiting for a green light. the product is at the n.i.h. then it will be a few months to get the human data that will allow us to pick -- fouad -- to stop it right away. president trump: over the next few months you think you'd have a vaccine? >> correct. phase two. president trump: you won't have a vaccine, you'll have a vaccine -- [indiscernible] -- [talking simultaneously] president trump: how long would that take? >> phase two will take a few months before going to phase three. president trump: you're talking within about a year. talking simultaneously] [indiscernible] >> we will be there in june. president trump: in a couple of months. right. i like the sound of a couple of months better. >> phase one initiation in june, not a completed vaccine. >> it would be a vaccine ready for testing in phase one. [talking simultaneously]
president trump: ready to use when? >> assuming that the vaccine is well tolerated -- [indiscernible] -- i think the question is how do we work with the f.d.a. to expedite that as fast as possible. some sort of fast-tracked program. as quickly as possible. president trump: what do you say to that, lenny? >> look, -- [indiscernible] -- dr. fauci is right to be cautious. vaccines have to be tested because there's precedent for vaccines to actually make diseases worse. you really don't want to make -- you don't want to rush and treat a million people and find out you're making 900,000 of them worse. president trump: good idea. >> so that's i think why dr. fauci is being cautious. i don't want to speak for him. so we need to prove that. i think that with our technology, by knowing that we have neutralizing antibodies, we know this approach worked for ebola. it wwe know it worked for merz
in animals. we have a greater degree of confidence that this would work sooner, i think. but -- president trump: ok. thank you very much. >> thank you for having us here. so i'm going to switch it up a little bit. we're not a vaccine company. we're a therapeutic company focused on anti-virals. president trump: let's talk about that. >> gill yard sciences has worked with a lot of people around the -- gill yid sciences has worked with many people around the table here. to be able to prevent and treat this disease is just extraordinary. president trump: we're saying 10 years but now we're into nine years because it could have been started earlier and somebody else didn't start it early, but we started it right away. now saying, i started off saying 10 years, now i'm down to nine years. do you think by the end of nine years, h.i.v. is where? >> i hope it's eliminated in the developed world. president trump: can you imagine? >> we have the ability to prevent it now.
if you can get people to really prevent it and treat everybody, i think it's certainly -- [talking simultaneously] president trump: if you remember back 10 years ago, how horrible it was. little beyond the 10 years and now -- [talking simultaneously] to think about what's happened. let's -- [talking simultaneously] >> same anti-viral to apply to coronavirus. we have a medicine which is like a decade-long development that's an anti-viral used to treat coronaviruses. the same viruses that -- the same family of sars and merz and we're hoping it has effect now against covid-19. we know in vitro it has very high effect. president trump: you have a medicine that's already involved with the coronaviruses. and now you have to see if it's specifically for this. when -- you can know that tomorrow, can't you? >> now the critical thing is to do clinical trials. we're in the process, we have two clinical trials going on in china that were started several
weeks ago. 400 patient trials each. they're getting close to halfway enrolled or -- president trump: any response? >> we don't know because they're double blind, randomized trials. we have to wait until the conclusion of the trial. we expect to get that information in april. we've been working with tony and the group at n.i.h. to have another protocol that will also be a protocol that we'll use in china, outside of china, here in the united states. to test for the virus. and we have two other clinical trials that we're going to initiate next week. president trump: anything here? >> the one trial had its first patients in nebraska and i think we're working on getting -- president trump: washington. >> washington state now. president trump: will you go to washington state? >> absolutely. the intention is to begin -- [indiscernible] -- coming days. so we're fully dedicated -- president trump: specifically the nursing home where they had an outbreak? >> yes, and the community of course that that touches. because all the health care workers and that.
the family members -- president trump: when will that take place? >> literally, i think, the next couple of days. [talking simultaneously] president trump: if tony's involved, it will be tomorrow morning. >> that's. it but this is a collaboration. we worked on the protocol together. obviously providing the investigational medicine. we're workinging hand in glove with many people around the table to make sure that, whether it's f.d.a. or c.d.c. or -- president trump: when will you know if it works? you already have this medicine. >> i think we'll know in the april time frame. [talking simultaneously] >> do you have any negative kickouts like utility analyses or reviews? >> there is a review and the trial in china, they'll probably look at some of that data in march. so far that would be only stopped for safety reasons. you really have to wait until the end of the trial to see efficacy. we're moving as fast as we can. i think everybody around the table is moving as fast as we can. on top of that, of course, we have to anticipate success. we're significantly investing in
the manufacturing facility and capacity. we've been working closely with the administration to -- [talking simultaneously] we have facilities that we're repurposing for the coronavirus -- [talking simultaneously] president trump: it would be tremendous if it works. because you're there. >> we have the trial in severe patients and more moderate patients. we're trying to understand this disease, where and when is the best place to treat -- president trump: very exciting. [talking simultaneously] don't disappoint us. you understand that? great company. really great company. [talking simultaneously] doctor, perhaps you'd like to say a few words. >> thank you. it's really an honor to be here with you. i'm really interested in hearing the efforts that are ongoing. you know we're working with you very closely now with many of you. it's been a great relationship. we're very interested, this is the message i want to send. we're very interested in facilitating the development of therapeutic diagnostics, vaccines, for the benefit of the american people. we of course want them to be
safe and efficacious but really look forward to working with you on this. thank you. president trump: thank you. you're going to do a fantastic job. thank you. please. >> mr. president, mr. vice president, i'm chief scientist for pfizer. we are very pleased to be here and for us it's been important when our major public health threats to come together, across the industry, with federal agencies. we were highly appreciative of the initiative you've taken in this powerful way to have all of us around this table. pfizer, as you know, is a proud american company. we have 170 years of experience, originally founded in brooklyn and headquartered in new york. and we have brought many vaccines, therapeutics of small and large types, for patients suffering from many different diseases, including infectious diseases. now, specifically for the
covid-19, the coronavirus, we have identified compounds, medicines that we have that we think, due to conscious -- [indiscernible] -- against related viruses, have good, high probability to vaccine against covid-19. in march we are confirming that assumption with laboratories work of access to using the live virus to confirm activity. that would allow us to work closely with dr. hahn here at f.d.a. and identify the -- [indiscernible] -- to bring it to patients that should happen if things go well this year and as soon as possible i can hear your encouragement to all of us. i also want to say that pfizer has 30 r&d manufacturing sites in the u.s. more than 30,000 americans involved in making or
discovering medicines and we're willing to share our experience, our capabilities as a team here to make sure that the public in america gets the best solutions. president trump: do you expect to be dealing with each other, your competitors, but in this case it's different. this is something we want to get done very quickly. do you expect to be sharing your own capabilities with pfizer and everybody else? >> absolutely. president trump: good. >> we all feel we should be one team here. president trump: i agree. i would appreciate that. >> a closing remark, we've had a tremendous partnership with n.i.h.. in many areas, in pioneering to bring sed sin -- medicine or advances forward with c.d.c. die logs and f.d.a. here. so -- dialogues and f.d.a. here. so we look forward to extending this relationship, to make sure at americans can, as fast as possible, given your encouragement to us, and have
different options to protect them, protection is by vaccines, to deal with those that are exposed, we need treatments and for those who are ill, we need treatments. it's not just one solution from this team we should offer multiple approaches. president trump: do you see that happening? i notice you have a few different varntes what have we're talking about. do you see that happening where maybe there are different, either therapeutics or vaccines or both? where you use combinations of each? maybe different areas. >> you are right on the -- [indiscernible] -- science. it is about combination. even looking at our colleagues ere, we have learned that if you have two different mechanisms and put them together as treatment, the likelihood of curing or -- [indiscernible] -- response is higher. we work on economy meantry mechanisms. president trump: i think it's fantastic. >> that's been the story of h.i.v. president trump: yeah. i love the economy meantry. if you can do, that i love the economy meantry.
[indiscernible] that's fantastic. thank you very much. -- complimentary. [indiscernible] that's fantastic. thank you very much. >> mr. president. mr. vice president. my name is joseph kim. i run a company out of pennsylvania. proud american biotech company with r&d and manufacturing in california as well. it's the leader in coronavirus vaccine development in the world. we have a phase two product for related merz, coronavirus vaccine. in phase two stage. when the new outbreak occurred, we applied our very innovative 21st century platform called d.n.a. medicines platform to covid-19. by getting the -- just the d.n.a. sequence of the virus, we're able to fully construct our vaccine within three hours. and we've been working on
precommit cal and -- preclinical and preparation work with the help of the f.d.a. and acceleration and really working very well together. our plan is to start the u.s.-based complin cal trials for covid-19 vack -- clinical trials for covid-19 in april of this year. followed by, shortly thereafter, a trial in china and south korea. there are a lot more infections in those areas. president trump: we can give you an area too. now we can. you take a look at seattle again. we can give you an area. if you don't mind. >> we've been collaborating with u.s. agencies like darpa, n.i.h., we've collaborated with dr. burks in h.i.v. vaccines many, many years ago. with existing resources and capacity, by end of this year, we can deliver about one million
doses. but to scale -- by end of this year. but to scale beyond that, we need your help, mr. president. we need to work with you and your agencies, barda and others, to help us scale our vaccines. to manufacture in america, to protect american public, also to lead the world in vaccine development from america. thank you very much. president trump: thank you very much. you'll have our help. thank you. >> mr. president, mr. vice president. i'm vice chairman and chief scientific officer for johnson & johnson. 30 in vaccine research since years. vaccine for h.i.v. at the moment working within the vaccine platform which has been deployed or is being deployed in h.i.v.. in the times of zika, as well as now ebola. we are working with phase two and phase three study with h.i.v. but same platform. with barda we have extensively
collaborated on the ebola vaccine. at the moment we are sax nating 1,000 people a day -- vaccinating 1,000 people a day, showing the safety of -- and the same vaccine platform we are now deploying for corona. the availability of the information on the virus mid january, we have been working day and night on getting to a vaccine. the first versions of that are being tested in animals at the moment. with positive results. and in parallel, the company has decided to upscaling now. ime to result will depend on manufacturing, safety. we have to work closely together with f.d.a. on that. before the year ends, hopefully in november, we have the first clinical data starting and early next year the results of that and at the same time we are looking for significant quantity of vaccines being already produced in that time frame. but you can't do anything else
at the -- than at the moment starting parallel. the biological clinical work and parallel doing upscaling and let's see where we end as fast as possible. president trump: did you have different concepts and methods than pfizer and johnson and johnson or -- all great companies. are you having different? some seem to be faster than others. they do seem to be different concepts. >> the difference in the concept , we are using a cold virus that is a place where you can place a piece of clone, ebola or h.i.v. so we treat the body with -- [indiscernible] -- and generate the antibodies like that. president trump: that's different from the others? >> it's different from the others but it's been used for many years now. it has been proven for many years that you can do it like that. we also have a validated upskating -- upscaling platform which can produce millions of doses in a very short time frame. that's a parallel process where we develop the cell line which, if we follow what we could do
with ebola, we could produce like up to hundreds of millions of vaccines in a small, let's say reasonably small facility for manufacturing. president trump: can you have it ready for next season? any of you? would you say for next season? >> the next season it should be ready. [talking simultaneously] [indiscernible] >> we have to be very careful here. if you vaccinate several hundred million people -- president trump: you have to make sure it works. >> works and is safe. [talking simultaneously] president trump: i agree. i agree. >> thank you. president trump: thank you. [indiscernible] >> the instructer from the c.d.c. really appreciate the chance to hear everyone. president trump: thank you. >> mr. president, mr. vice president, thank you for saving the most exciting company for last. [laughter] so we're nova vax. we're down the street in maryland. we're a vaccine company. we make a prominent nanoparticles. we make respiratory vaccines. we have two and three phase
trials. we have vaccines where we vaccinated pregnant women to protect infants from r.s.v. disease in the youngest kids. we have a flu vaccine, we all know we need a better flu vaccine. we have one in phase three trials. we're going to under blind in four weeks. exciting time to -- time for the company. but we are a company that's focused on emerging infectious diseases. we've made two coronavirus vaccines. we made one for sars and merz. tested one for merz, showed 100% infection protection. we have an ebola vaccine that, with the n.i.h., showed in four different nonhuman prime ate studies, that we had 100% protection at extremely low-doses. and we've made a pandemic flu vaccine for others. we've twice now taken from the gene sequence to the first in human studies, done them in 90 days and published in the new england journal and we're once again doing the same thing.
gene sequence was identified, i think published on january 10, we've taken our same, prominent nanoparticle platform and have been in animal studies for a couple weeks. we expect data this week from one of them. president trump: clone? >> on clone, yes -- corona, yes. we're going into nonhuman pry might -- primates this week with the candidate. president trump: what do you think in terms of timing? >> what you hear around the table. we can get it into humans and the may, june timetable. n a phase one study. we'll have bright ate data. president trump: those -- primate data. president trump: those are nheard of speeds, right? >> we're trying to identify scale so that we can get to the billion unit scale both where we have a vaccine and --
[indiscernible] -- and you put those together, you get the most promising result, we think. we need and have good relationships with the f.d.a. and to work with the f.d.a. to see where, instead of waiting 30 days to get to an -- [indiscernible] -- you get in 10 days or 20. whatever the number. is there are a lot of things we can do with the f.d.a. and we need money. we're a biotech company. i'm not one of the larger pharma companies. so we need money to get scale. president trump: [indiscernible] -- >> have worked with other companies. on this particular instance we have not yet. but can. president trump: dr. steven hahn is the new head of the f.d.a. he's one of the most respected people in the country. this is the man we wanted and this is the man we got. you didn't know you were going to be hit with this your first month. been here for a couple of months and this was pretty big. deborah, would you like to say
something? >> well, thank you. it's a privilege to be here. thank you, mr. president, mr. vice president. i think what was exciting to hear around the table is you have a potential for a bridge. a bridge between the therapeutics while we work on the vaccines. that's the most proming -- promising piece for the american people. to know there's technology that can be used as an immediate bridge and then as we work on the vaccines, i think making sure that we've tested all of the anti-virals that you in your collection against this particular virus, do i see 50's across the board, many of you have anti-viral medication and i think just to assure the american people that we have tried using our innovators to actually screen all the current drugs for potential activity against this virus would be key. but i think this is very promising with this linkage that you put together in this room between therapeutics and vaccines and antibiotic boddies. very encouraging.
president trump: very exciting. and the speed is exciting too. anybody else have something to say? >> also something on the screening. we set up already an industry consortium where everyone is now able to submit biotech or pharmaceuticals to sub matt: to a screening -- submit to a screening which is set up for everybody supporting barda and europe. president trump: it will move rapidly. media, would you like it ask any questions of any of the geniuses around here? president trump: what economic stimulus measures are you considering to boost the economy as a result of the virus? president trump: i guess the markets are up today. our country is strong economyly -- economically. this was something that came out of china that was a big surprise to the world. it happened just a few weeks ago . it i'm sure the fed is looking at it. i hope the fed is looking at it. she thub. but a lot of the central bank are looking at interest stimulus and one thing i want to add, we're here for the whole world. this is a world cure, not just the united states.
we want to take care of the united states. [captioning performed by the national captioning institute, which is responsible for its caption content and accuracy. visit ncicap.org] [captions copyright national cable satellite corp. 2020] >> all of this will be available shortly at c-span.org/coronavirus we're going to leave the president's comments here to honor our 41-year commitment of covering the u.s. house live coming in next for bill debate on four measures. the house will resume postponed on the questions at a later time. does the urpose gentleman from guam seek recognition? mr. san nicolas: mr. speaker, i ask the house suspend the rules pass the bill h.r. 5931, the f.h.a. for small-dollar mortgages act of 2020 as amounteded. -- as amended. the speaker pro tempore: the clerk will report the title of the bill. the clerk: a bill to require a affects of f.h.a. mortgage policies, practices, small-dollar mortgage lending and for other purposes. the speaker pro tempore: pursuant to the rule, the gentleman from